 1. Patient is currently enrolled in a Novartis OGD or GMA-sponsored or Incyte-sponsored clinical study where Incyte can delegate the sponsorship to a preferred CRO, if applicable that is approved to enroll into this rollover study, is receiving ruxolitinib and has fulfilled all of the requirements of the parent protocol. 